Management of Elevated Estradiol in Males on Testosterone Therapy

Introduction to Estradiol Management

The American Urological Association recommends clinical monitoring and consideration of aromatase inhibitor therapy for males on testosterone therapy with estradiol levels above 60 pg/mL, especially if they develop breast symptoms or sexual dysfunction symptoms 1

The assessment of breast symptoms, including gynecomastia, breast pain, and nipple tenderness, is crucial in males on testosterone therapy with elevated estradiol levels 1, 5, 6
The measurement of luteinizing hormone (LH) levels can help assess the degree of hypothalamic-pituitary suppression in these patients 1, 5, 6
For asymptomatic patients, observation with clinical monitoring is appropriate, and the current testosterone therapy can be continued without modification 1, 3, 6
The target estradiol reduction is to less than 40 pg/mL while maintaining testosterone levels in the therapeutic range (300-1000 ng/dL) 5

The American Urological Association guideline states that breast symptoms may sometimes abate spontaneously with continued monitoring, and treatment decisions should incorporate symptomatology, not laboratory values in isolation 1
Elevated estradiol levels are expected during testosterone therapy due to peripheral aromatization of testosterone to estradiol in adipose tissue 1, 2, 3, 4